To analyse our HSA-CD39 fusion protein in vitro, we used a flow diverter nitinol BlueOxide DERIVO embolisation device, which has been evaluated for the treatment of intracranial aneurysms in clinical trials (Figure 7 and Figure 8) [76]. This evidence concerns the gene ENTPD1 and Dilatation of the cerebral artery.